Idiopathic Pulmonary Fibrosis Market

DelveInsight’s ‘Idiopathic Pulmonary Fibrosis (IPF) - Market Insights, Epidemiology and Market Forecast-2030 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of IPFs in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.


The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Idiopathic Pulmonary Fibrosis (IPF) from 2017 to 2030 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

 

Study Period: 2017–2030

Idiopathic Pulmonary Fibrosis (IPF) - Disease Understanding and Treatment Algorithm

Idiopathic Pulmonary Fibrosis (IPF) is a rare, chronic, progressive fibrosing interstitial pneumonia which is found to affect the middle-aged and older adults; and affects lung tissue (alveoli in particular) by either thickening, stiffening, or persistent and progressive scarring (fibrosis) which increases irreversibly over time. If an individual has IPF, scarring affects the air sacs, limiting the amount of oxygen that gets into the blood. With less oxygen in the blood, one can get breathlessness from everyday activities, like walking. This group of lung disorders is also known as ‘Diffuse Parenchymal Lung Diseases,’ which is characterized by a broader umbrella of ‘Interstitial Lung Diseases (IDLs).

 

The DelveInsight Idiopathic Pulmonary Fibrosis (IPF) market report gives the thorough understanding of the Idiopathic Pulmonary Fibrosis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Idiopathic Pulmonary Fibrosis in the US, Europe and Japan.

Idiopathic Pulmonary Fibrosis Epidemiology

The Idiopathic Pulmonary Fibrosis (IPF) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Prevalent cases of IPF, Age-specific cases, Prevalence by severity and Gender-specific cases of IPF) scenario of Idiopathic Pulmonary Fibrosis (IPF) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2030.


According to DelveInsight, the total number of prevalent cases of Idiopathic Pulmonary Fibrosis (IPF) in 7 MM was found to be 229,170, in the year 2017.

Idiopathic Pulmonary Fibrosis Drug Chapters

This segment of the Idiopathic Pulmonary Fibrosis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.


Currently, there are two approved drugs in the market; Esbriet (Pirfenidone) and Ofev (Nintedanib) aims at slowing down the disease progression through acting like anti-fibrotic mediators. Nintedanib is a potent intracellular inhibitor of the receptor tyrosine kinases PDGFR, FGFR, vascular endothelial growth factor receptor (VEGFR) and non-receptor tyrosine kinases of the Src family; Pirfenidone, on the other, is responsible for reducing markers of oxidative stress, reducing the proliferation of lung fibroblasts and their differentiation into myofibroblasts by attenuating key TGF-β-induced signalling pathways (i.e., Smad3, p38, and Akt), reducing the expression of TGF-β-induced heat-shock protein 47 (HSP47), which is involved in processing/secretion of procollagen, and reducing expression of α smooth muscle actin (α-SMA) and collagen type 1.

Idiopathic Pulmonary Fibrosis Market Outlook

The Idiopathic Pulmonary Fibrosis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.


This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.


According to DelveInsight, the market of Idiopathic Pulmonary Fibrosis in 7MM was found to be USD 1,510.4 Million in 2017, and is expected to increase during the course of the study period (2017–2030).


Among the 7MM, the United States accounts for the largest market size of IPF, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

 

Idiopathic Pulmonary Fibrosis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017–2030. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Idiopathic Pulmonary Fibrosis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Idiopathic Pulmonary Fibrosis Report Key Strengths

  • 1 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Idiopathic Pulmonary Fibrosis Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Idiopathic Pulmonary Fibrosis market
  • Organize sales and marketing efforts by identifying the best opportunities for Idiopathic Pulmonary Fibrosis market
  • To understand the future market competition in the Idiopathic Pulmonary Fibrosis market.


What is Idiopathic Pulmonary Fibrosis?

Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive disease characterized by the aberrant accumulation of fibrotic tissue in the lungs parenchyma, associated with significant morbidity and poor prognosis.


What was the Idiopathic Pulmonary Fibrosis market size in the 7 major markets (7MM)?

Idiopathic Pulmonary Fibrosis Market Size was 1,510 Million in the 7MM in 2017

 

Which geography accounted for the largest Idiopathic Pulmonary Fibrosis market size?

The US accounted for the largest Idiopathic Pulmonary Fibrosis market size among the 7MM


What are the Idiopathic Pulmonary Fibrosis market drivers?

The grant of special regulatory designations, several therapies in the pipeline from various companies, an increase in the prevalence of fibrotic diseases are the Idiopathic Pulmonary Fibrosis market drivers


What are the Idiopathic Pulmonary Fibrosis market barriers?

The prognosis of patients with Idiopathic Pulmonary Fibrosis remains poor, lack of accurate diagnostic procedures and, specific validating biomarkers, Idiopathic Pulmonary Fibrosis is associated with high mortality rates are the Idiopathic Pulmonary Fibrosis market barriers


How many companies are developing drugs for Idiopathic Pulmonary Fibrosis?

MediciNova, FibroGen, Kadmon Corporation, Promedior, Inc, Galapagos NV are developing drugs for Idiopathic Pulmonary Fibrosis

1.    Key Insights

2.    Idiopathic Pulmonary Fibrosis Market Overview at a Glance

2.1.     Market Share (%) Distribution of Idiopathic Pulmonary Fibrosis in 2017

2.2.     Market Share (%) Distribution of Idiopathic Pulmonary Fibrosis in 2028

3.    Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)

3.1.     Introduction

3.2.     Statistics about Idiopathic Pulmonary Fibrosis

3.3.     Staging of Idiopathic Pulmonary Fibrosis

3.4.     Risk Factors and Disease Causes

3.5.     Symptoms

3.6.     Pathogenesis

3.7.     Diagnosis

4.    Epidemiology and Patient Population

4.1.     Key Findings

4.2.     7MM Prevalent Population of Idiopathic Pulmonary Fibrosis

5.    Country Wise-Epidemiology of Idiopathic Pulmonary Fibrosis

5.1.  United States

5.1.1.   Prevalent cases of Idiopathic Pulmonary Fibrosis in the United States

5.1.2.   Prevalent Population of Idiopathic Pulmonary Fibrosis by severity

5.1.3.   Gender-specific Idiopathic Pulmonary Fibrosis Prevalence

5.1.4.   Age-specific Idiopathic Pulmonary Fibrosis Prevalence

5.2.  EU5

5.2.1.   Prevalent Population of Idiopathic Pulmonary Fibrosis in EU5

5.2.2. Germany

5.2.2.1.   Prevalent Population of Idiopathic Pulmonary Fibrosis

5.2.2.2.   Prevalent Population of Idiopathic Pulmonary Fibrosis by severity

5.2.2.3.   Gender-specific Idiopathic Pulmonary Fibrosis Prevalence

5.2.2.4.   Age-specific Idiopathic Pulmonary Fibrosis Prevalence

5.2.3. France

5.2.3.1.   Prevalent Population of Idiopathic Pulmonary Fibrosis

5.2.3.2.   Prevalent Population of Idiopathic Pulmonary Fibrosis by severity

5.2.3.3.   Gender-specific Idiopathic Pulmonary Fibrosis Prevalence

5.2.3.4.   Age-specific Idiopathic Pulmonary Fibrosis Prevalence

5.2.4. Italy

5.2.4.1.   Prevalent Population of Idiopathic Pulmonary Fibrosis

5.2.4.2.   Prevalent Population of Idiopathic Pulmonary Fibrosis by severity

5.2.4.3.   Gender-specific Idiopathic Pulmonary Fibrosis Prevalence

5.2.4.4.   Age-specific Idiopathic Pulmonary Fibrosis Prevalence

5.2.5. United Kingdom

5.2.5.1.   Prevalent Population of Idiopathic Pulmonary Fibrosis

5.2.5.2.   Prevalent Population of Idiopathic Pulmonary Fibrosis by severity

5.2.5.3.   Gender-specific Idiopathic Pulmonary Fibrosis Prevalence

5.2.5.4.   Age-specific Idiopathic Pulmonary Fibrosis Prevalence

5.2.6. Spain

5.2.6.1.   Prevalent Population of Idiopathic Pulmonary Fibrosis

5.2.6.2.   Prevalent Population of Idiopathic Pulmonary Fibrosis by severity

5.2.6.3.   Gender-specific Idiopathic Pulmonary Fibrosis Prevalence

5.2.6.4.   Age-specific Idiopathic Pulmonary Fibrosis Prevalence

5.3.  Japan

5.3.1.   Prevalent Population of Idiopathic Pulmonary Fibrosis

5.3.2.   Prevalent Population of Idiopathic Pulmonary Fibrosis by severity

5.3.3.   Gender-specific Idiopathic Pulmonary Fibrosis Prevalence

5.3.4.   Age-specific Idiopathic Pulmonary Fibrosis Prevalence

6.    Current Treatment Practices

6.1.     ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis (An Update of 2011 Clinical Practice Guideline)

6.2.     Patient Journey

7.    Unmet Needs

8.    Organizations contributing toward IPF

9.    KOL’s Views: Idiopathic Pulmonary Fibrosis

10. Case Reports

10.1.  Idiopathic Pulmonary Fibrosis: As case Discussion in the US

10.2.  Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report of Europe

10.3.  Nintedanib prevented fibrosis progression and lung cancer growth in idiopathic pulmonary fibrosis – A Japanese Case Report

11. Marketed Products

11.1.Esbriet (Pirfenidone): InterMune Inc.

11.1.1. Product Description

11.1.2. Regulatory Milestones

11.1.3. Advantages & Disadvantages

11.1.4. Safety and Efficacy of Esbriet

11.1.5. Side effects of Esbriet

11.1.6. Product Profile

11.2.Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Advantages and Disadvantages

11.2.4. Safety and Efficacy of Ofev

11.2.5. Side effects of Ofev

11.2.6. Product Profile

12. Emerging Therapies

12.1.  Key Cross Competition

12.2.Tipelukast: MediciNova

12.2.1. Drug Description

12.2.2. Clinical Development

12.2.3. Clinical Trials Information

12.2.4. Safety and Efficacy

12.2.5. Product Profile

12.3.Pamrevlumab: FibroGen

12.3.1. Drug Description

12.3.2. Regulatory Milestones

12.3.3. Other Development Activities

12.3.4. Clinical Development

12.3.5. Clinical Trials Information

12.3.6. Safety and Efficacy

12.3.7. Product Profile

12.4.KD025: Kadmon Corporation, LLCs

12.4.1. Drug Description

12.4.2. Other Development Activities

12.4.3. Clinical Development

12.4.4. Clinical Trials Information

12.4.5. Safety and Efficacy

12.4.6. Product Profile

12.5.PRM 151: Promedior, Inc.

12.5.1. Drug Description

12.5.2. Regulatory Milestones

12.5.3. Other Development Activities

12.5.4. Clinical Development

12.5.5. Clinical Trials Information

12.5.6. Safety and Efficacy

12.5.7. Product Profile

12.6.GLPG1690: Galapagos NV

12.6.1. Drug Description

12.6.2. Regulatory Milestones

12.6.3. Other Development Activities

12.6.4. Clinical Development

12.6.5. Clinical Trials Information

12.6.6. Safety and Efficacy

12.6.7. Product Profile

13. Other Promising Candidates

13.1.CC-90001: Celgene Corporation

13.1.1. Drug Description

13.1.2. Clinical Development

13.1.3. Clinical Trials Information

13.1.4. Safety and Efficacy

13.1.5. Product Profile

13.2.LT-1001: Beijing Tide Pharmaceutical

13.2.1. Drug Description

13.2.2. Other Development Activities

13.2.3. Clinical Development

13.2.4. Clinical Trials Information

13.2.5. Safety and Efficacy

13.2.6. Product Profile

13.3.LT-1002: Chong Kun Dang Pharmaceutical

13.3.1. Drug Description

13.3.2. Other Development Activities

13.3.3. Clinical Development

13.3.4. Clinical Trials Information

13.3.5. Product Profile

13.4.BG00011: Biogen Inc.

13.4.1. Drug Description

13.4.2. Regulatory Milestones

13.4.3. Other Development Activities

13.4.4. Clinical Development

13.4.5. Clinical Trials Information

13.4.6. Safety and Efficacy

13.4.7. Product Profile

13.5.PBI4050: ProMetic Life Sciences

13.5.1. Drug Description

13.5.2. Regulatory Milestones

13.5.3. Other Development Activities

13.5.4. Clinical Development

13.5.5. Clinical Trials Information

13.5.6. Safety and Efficacy

13.5.7. Product Profile

13.6.TD139: Galecto Biotech

13.6.1. Drug Description

13.6.2. Other Development Activities

13.6.3. Clinical Development

13.6.4. Clinical Trials Information

13.6.5. Safety and Efficacy

13.6.6. Product Profile

13.7.VAY736: Novartis

13.7.1. Drug Description

13.7.2. Other Development Activities

13.7.3. Clinical Development

13.7.4. Clinical Trials Information

13.7.5. Product Profile

13.8.TAS-115: Taiho Pharmaceutical

13.8.1. Drug Description

13.8.2. Clinical Development

13.8.3. Clinical Trials Information

13.8.4. Product Profile

13.9.ND-L02-s0201: Nitto Denko Corporation

13.9.1. Drug Description

13.9.2. Other Development Activities

13.9.3. Clinical Development

13.9.4. Clinical Trials Information

13.9.5. Safety and Efficacy

13.9.6. Product Profile

13.10.           Nalbuphine ER: Trevi Therapeutics

13.10.1.    Drug Description

13.10.2.    Clinical Development

13.10.3.    Clinical Trials Information

13.10.4.    Product Profile

13.11.           RVT-1601: Respivant Sciences

13.11.1.    Drug Description

13.11.2.    Clinical Development

13.11.3.    Clinical Trials Information

13.11.4.    Safety and Efficacy

13.11.5.    Product Profile

13.12.           Gefapixant: Merck & Co.

13.12.1.    Drug Description

13.12.2.    Other Development Activities

13.12.3.    Clinical Development

13.12.4.    Clinical Trials Information

13.12.5.    Safety and Efficacy

13.12.6.    Product Profile

14. Idiopathic Pulmonary Fibrosis: Market Analysis

14.1.  Key Findings

14.2.  Total Market Size of Idiopathic Pulmonary Fibrosis in 7MM

14.3.  Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in 7MM

15. Market Size of Idiopathic Pulmonary Fibrosis by Country

15.1.United States Market Analysis

15.1.1. Market Size of Idiopathic Pulmonary Fibrosis in the US

15.1.2. Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in the US

15.2.EU5 Market Outlook

15.2.1.  Germany

15.2.1.1. Market Size of Idiopathic Pulmonary Fibrosis in Germany

15.2.1.2. Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Germany

15.2.2.  France

15.2.2.1. Market Size of Idiopathic Pulmonary Fibrosis in France

15.2.2.2. Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in France

15.2.3.  Italy

15.2.3.1. Market Size of Idiopathic Pulmonary Fibrosis in Italy

15.2.3.2. Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Italy

15.2.4.  United Kingdom

15.2.4.1. Market Size of Idiopathic Pulmonary Fibrosis in the UK

15.2.4.2. Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in the UK

15.2.5.  Spain

15.2.5.1. Market Size of Idiopathic Pulmonary Fibrosis in Spain

15.2.5.2. Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Spain

15.3.Japan: Market Analysis

15.3.1. Market Size of Idiopathic Pulmonary Fibrosis in Japan

15.3.2. Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Japan

16. Market Drivers of Idiopathic Pulmonary Fibrosis

17. Market Barriers of Idiopathic Pulmonary Fibrosis

18. Appendix

18.1.  Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

List Of Tables:


Table 1: Expected 1-year probability of death in patients with idiopathic pulmonary fibrosis

Table 2: The GAP (Gender, Age, and Physiology) score

Table 3: The GAP index and staging system

Table 4: High resolution computed tomography criteria for up pattern

Table 5: 7MM, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Table 6: The United States, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Table 7: The United States, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017–2030

Table 8: The United States, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Table 9: The United States, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Table 10: EU5, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Table 11: Germany, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Table 12: Germany, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017–2030

Table 13: Germany, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Table 14: Germany, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Table 15: France, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Table 16: France, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017–2030

Table 17: France, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Table 18: France, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Table 19: Italy, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Table 20: Italy, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017–2030

Table 21: Italy, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Table 22: Italy, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Table 23: The United Kingdom, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Table 24: The United Kingdom, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017–2030

Table 25: The United Kingdom, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Table 26: The United Kingdom, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Table 27: Spain, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Table 28: Spain, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017–2030

Table 29: Spain, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Table 30: Spain, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Table 31: Japan, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Table 32: Japan, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017–2030

Table 33: Japan, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Table 34: Japan, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Table 35: Dosage of Pirfenidone

Table 36: Dosage of Nintedanib

Table 37: Interpretation of Strong and Conditional Recommendations for Stakeholders (Patients, Clinicians, and Health Care Policy-Makers):

Table 38: Comparison of recommendations in 2015 and 2011 IPF Guidelines

Table 39: Organizations contributing toward IPF

Table 40: Key Cross Analysis of Emerging Therapies


List Of Figures:


Figure 1: Risk factors associated with IPF

Figure 2: IPF associated clubbing of the fingertips

Figure 3: Stages of the pathogenesis of IPF

Figure 4: A schematic representing the current model for the pathogenesis of IPF

Figure 5: Possible mechanisms of fibrogenesis in IPF

Figure 6: Chest radiograph of a patient with idiopathic pulmonary fibrosis showing bilateral lower lobe reticular opacities (red circles)

Figure 7: Sub pleural honeycombing in IPF diagnosed patients

Figure 8: ATS/ERS criteria for the diagnosis of idiopathic pulmonary fibrosis in the absence of surgical lung biopsy (2000).

Figure 9: Combination of high-resolution computed tomography and surgical lung biopsy for the diagnosis of IPF (requires multidisciplinary discussion)

Figure 10: Diagnostic algorithm for idiopathic pulmonary fibrosis (IPF). Patients with suspected IPF

Figure 11: 7MM, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Figure 12: The United States, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Figure 13: The United States, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017–2030

Figure 14: The United States, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Figure 15: The United States, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Figure 16: EU5, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Figure 17: Germany, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Figure 18: Germany, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017–2030

Figure 19: Germany, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Figure 20: Germany, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Figure 21: France, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Figure 22: France, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017–2030

Figure 23: France, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Figure 24: France, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Figure 25: Italy, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Figure 26: Italy, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017–2030

Figure 27: Italy, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Figure 28: Italy, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Figure 29: The United Kingdom, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Figure 30: The United Kingdom, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017–2030

Figure 31: The United Kingdom, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Figure 32: The United Kingdom, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Figure 33: Spain, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Figure 34: Spain, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017–2030

Figure 35: Spain, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Figure 36: Spain, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Figure 37: Japan, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Figure 38: Japan, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017–2030

Figure 39: Japan, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

Figure 40: Japan, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030

  • Tags:
  • Idiopathic Pulmonary Fibrosis marke...
  • Idiopathic Pulmonary Fibrosis marke...
  • Idiopathic Pulmonary Fibrosis marke...
  • Idiopathic Pulmonary Fibrosis marke...
  • Idiopathic Pulmonary Fibrosis marke...
  • Idiopathic Pulmonary Fibrosis marke...
  • Idiopathic Pulmonary Fibrosis pipel...
  • Idiopathic Pulmonary Fibrosis treat...
  • Idiopathic Pulmonary Fibrosis drugs
  • Idiopathic Pulmonary Fibrosis sales...
  • Idiopathic Pulmonary Fibrosis marke...
  • Idiopathic Pulmonary Fibrosis disea...
  • Idiopathic Pulmonary Fibrosis epide...
  • Idiopathic Pulmonary Fibrosis

Forward to Friend

Need A Quote